{"transactions":[{"id":697348,"issuer":{"id":8081,"kind":"organization","name":"Alzamend Neuro, Inc."},"owners":[{"id":26689,"kind":"person","name":"Jackman Stephan","position":1,"cik":"0001864257","reported_name":"Jackman Stephan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-08-05T01:00:16.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 13, 2025, the Board of Directors of the Issuer granted stock options to Mr. Jackman to purchase 450,000 shares of Common Stock.  Fifty percent (50%) of these options vested and became exercisable on the date that receipt of approval of the option grants by the Issuer's stockholders.  Stockholder approval was obtained on April 17, 2026, which was the date that these options vested and became exercisable.  The remaining 50% vest in equal monthly increments over 24 months beginning May 17, 2026."}],"balance_after":450000,"derivative":{"exercise_price":2.33,"expiration_date":"2035-11-12","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001214659-26-009586","document":"marketforms-73673.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864257/000121465926009586/marketforms-73673.xml","form_type":"5"}},{"id":1908491,"issuer":{"id":8081,"kind":"organization","name":"Alzamend Neuro, Inc."},"owners":[{"id":26689,"kind":"person","name":"Jackman Stephan","position":1,"cik":"0001864257","reported_name":"Jackman Stephan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-05-02T20:30:26.000Z","date":"2023-04-28","kind":"purchase","planned":false,"acquired":true,"shares":37000,"price":0.5405,"value":19998.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $0.5405. The range of purchase prices on the transaction date was $0.5398 to $0.5499 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001214659-23-006373","document":"marketforms-61359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864257/000121465923006373/marketforms-61359.xml","form_type":"4"}},{"id":2101626,"issuer":{"id":8081,"kind":"organization","name":"Alzamend Neuro, Inc."},"owners":[{"id":26689,"kind":"person","name":"Jackman Stephan","position":1,"cik":"0001864257","reported_name":"Jackman Stephan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-30T21:30:18.000Z","date":"2022-11-29","kind":"grant","acquired":true,"shares":2000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 29, 2022, Mr. Jackman was granted options to purchase 2,000,000 shares of common stock of Alzamend Neuro, Inc. (the \"Issuer\"), of which (i) 50% would vest if the Issuer completed and announced topline data, within three years from the grant date, from a Phase II clinical trial of AL001 that would support a new drug application (\"NDA\") in Alzheimer's Disease and (ii) 50% would vest if the Issuer completed and announced topline data, within four years from the grant date, from a Phase II clinical trial of ALZN002 that would support an NDA in Alzheimer's Disease."}],"balance_after":0,"derivative":{"exercise_price":1.17,"expiration_date":"2032-11-28","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001214659-22-014319","document":"marketforms-57706.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864257/000121465922014319/marketforms-57706.xml","form_type":"4"}},{"id":2154171,"issuer":{"id":8081,"kind":"organization","name":"Alzamend Neuro, Inc."},"owners":[{"id":26689,"kind":"person","name":"Jackman Stephan","position":1,"cik":"0001864257","reported_name":"Jackman Stephan","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-09-20T20:30:15.000Z","date":"2022-09-19","kind":"purchase","acquired":true,"shares":8500,"price":1.2252,"value":10414.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $1.2252. The range of purchase prices on the transaction date was $1.225 to $1.23 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price."}],"balance_after":8500,"source":{"system":"sec-edgar","filing":"0001214659-22-011325","document":"marketforms-57156.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864257/000121465922011325/marketforms-57156.xml","form_type":"4"}}]}